Zimmer Biomet reported 580 job cuts: Barclays kept Hold on Zimmer Biomet stock

Published on 10/08/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zimmer Biomet stock costs EUR 78.96 on October 8, 2026 after EUR 79.04, minus 0.10 percent. Barclays kept a USD 100.00 target.

Zimmer Biomet US98956P1021 zeigt Makroaufnahme der porösen Titanoberfläche eines orthopädischen Implantats in dramatischem Streiflicht, Illustration mit AI erstellt.

Zimmer Biomet (ISIN US98956P1021) reported plans affecting up to 580 of 730 jobs at its Winterthur site, as Swiss Observer reported on September 10, 2026. The proposed reductions were linked to a restructuring of manufacturing operations and a consultation with employees. On October 7, 2026, Barclays analyst Matt Miksic maintained a Hold rating and a USD 100.00 price target, according to Markets Insider.

Winterthur restructuring reaches 730 jobs

The Winterthur proposal covers up to 580 positions at a site employing 730 people. That would put the maximum potential reduction at 79.45 percent of the local workforce, although the consultation will determine the final scope.

The Swiss Observer report said the company had not approved a final redundancy total and that employee representatives were entering the consultation process. For investors, the distinction matters because the announced figure describes a maximum proposal rather than a completed closure.

Second-quarter growth supports the contrast

Zimmer Biomet delivered USD 2.177 billion in second-quarter 2026 revenue, up 4.80 percent from USD 2.077 billion in the second quarter of 2025, according to the company's earnings-call transcript published by Yahoo Finance. The same call reported adjusted earnings per share of USD 2.07, unchanged from the second quarter of 2025, while GAAP diluted earnings per share increased to USD 1.03 from USD 0.77.

Management also raised full-year 2026 organic constant-currency revenue growth guidance to 2.25 percent to 3.25 percent from 1.00 percent to 3.00 percent. Adjusted earnings per share guidance moved to USD 8.47 to USD 8.59 from USD 8.40 to USD 8.55, while the company cited continued investment in its US commercial organization as a margin factor.

Barclays keeps a cautious valuation view

Barclays' USD 100.00 target stands above the EUR reference quote, so a percentage distance between the two values would mix currencies. Markets Insider said Barclays kept its Hold rating, while the article also cited a Hold view from Citi dated October 5, 2026 and a Buy rating from RBC Capital dated October 1, 2026.

Zimmer Biomet's second-quarter operating picture therefore combines 4.80 percent reported revenue growth with flat adjusted earnings per share and a restructuring proposal affecting 580 local jobs. The next valuation signal will depend on whether the company converts its upgraded growth guidance into stronger margins while managing the manufacturing changes.

Stock remains below its yearly high

Zimmer Biomet stock was trading at EUR 78.96 at Lang & Schwarz on October 8, 2026 at 11:09 a.m. CEST, minus 0.10 percent versus the prior close of EUR 79.04. The primary listing is on the NYSE, where the stock's 52-week range was USD 79.12 to USD 106.88 and market capitalization was USD 17.1 billion as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Zimmer Biomet stock.